PORTFOLIO NEWS RAPT Therapeutics Announces Biomarker Data from Phase 1B Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis March 28, 2022 Read More » Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results March 24, 2022 Read More » Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer March 23, 2022 Read More » Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis March 22, 2022 Read More » NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022 March 21, 2022 Read More » ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update March 21, 2022 Read More » eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update March 16, 2022 Read More » RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results March 10, 2022 Read More » NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting March 8, 2022 Read More » A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers March 4, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
RAPT Therapeutics Announces Biomarker Data from Phase 1B Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis March 28, 2022 Read More »
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer March 23, 2022 Read More »
Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis March 22, 2022 Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update March 21, 2022 Read More »
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update March 16, 2022 Read More »
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results March 10, 2022 Read More »
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting March 8, 2022 Read More »
A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers March 4, 2022 Read More »
